Literature DB >> 19121372

Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression.

A Giralt1, T Rodrigo, E D Martín, J R Gonzalez, M Milà, V Ceña, M Dierssen, J M Canals, J Alberch.   

Abstract

The involvement of brain-derived neurotrophic factor (BDNF) in cognitive processes and the decrease in its expression in Huntington's disease suggest that this neurotrophin may play a role in learning impairment during the disease progression. We therefore analyzed the onset and severity of cognitive deficits in two different mouse models with the same mutant huntingtin but with different levels of BDNF (R6/1 and R6/1:BDNF+/- mice). We observed that BDNF modulates cognitive function in different learning tasks, even before the onset of motor symptoms. R6/1:BDNF+/- mice showed earlier and more accentuated cognitive impairment than R6/1 mice at 5 weeks of age in discrimination learning; at 5 weeks of age in procedural learning; and at 9 weeks of age in alternation learning. At the earliest age at which cognitive impairment was detected, electrophysiological analysis was performed in the hippocampus. All mutant genotypes showed reduced hippocampal long term potentiation (LTP) with respect to wild type but did not show differences between them. Thus, we evaluated the involvement of BDNF-trkB signaling and glutamate receptor expression in the hippocampus of these mice. We observed a decrease in phospholipaseCgamma activity, but not ERK, in R61, BDNF+/- and R6/1:BDNF+/- hippocampus at the age when LTP was altered. However, a specific decrease in the expression of glutamate receptors NR1, NR2A and GluR1 was detected only in R6/1:BDNF+/- hippocampus. Therefore, these results show that BDNF modulates the learning and memory alterations induced by mutant huntingtin. This interaction leads to intracellular changes, such as specific changes in glutamate receptors and in BDNF-trkB signaling through phospholipaseCgamma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19121372     DOI: 10.1016/j.neuroscience.2008.11.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  39 in total

1.  Naturally occurring genetic variability in expression of Gsta4 is associated with differential survival of axotomized rat motoneurons.

Authors:  Mikael Ström; Faiez Al Nimer; Rickard Lindblom; Jens Randel Nyengaard; Fredrik Piehl
Journal:  Neuromolecular Med       Date:  2011-12-08       Impact factor: 3.843

2.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

3.  Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61 ) levels.

Authors:  Jian Xu; Pradeep Kurup; Garikoitz Azkona; Tyler D Baguley; Ana Saavedra; Angus C Nairn; Jonathan A Ellman; Esther Pérez-Navarro; Paul J Lombroso
Journal:  J Neurochem       Date:  2015-09-17       Impact factor: 5.372

4.  RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.

Authors:  Núria Martín-Flores; Joan Romaní-Aumedes; Laura Rué; Mercè Canal; Phil Sanders; Marco Straccia; Nicholas D Allen; Jordi Alberch; Josep M Canals; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Mol Neurobiol       Date:  2015-04-16       Impact factor: 5.590

5.  BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.

Authors:  Yuxiang Xie; Michael R Hayden; Baoji Xu
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

6.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

7.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

8.  Conditional BDNF Delivery from Astrocytes Rescues Memory Deficits, Spine Density, and Synaptic Properties in the 5xFAD Mouse Model of Alzheimer Disease.

Authors:  Benoit de Pins; Carmen Cifuentes-Díaz; Amel Thamila Farah; Laura López-Molina; Enrica Montalban; Anna Sancho-Balsells; Ana López; Silvia Ginés; José María Delgado-García; Jordi Alberch; Agnès Gruart; Jean-Antoine Girault; Albert Giralt
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

Review 9.  ERK in learning and memory: a review of recent research.

Authors:  Sheng Peng; Yan Zhang; Jiannan Zhang; Hua Wang; Bingxu Ren
Journal:  Int J Mol Sci       Date:  2010-01-13       Impact factor: 6.208

10.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.